Related Experiment Video

Updated: Nov 18, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.8K

The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma

Melissa Abel1, Aaron Burkenroad1, Alexander Sun1

  • 1Ronald Reagan UCLA Medical Center, Los Angeles, CA.

Clinical Genitourinary Cancer
|February 9, 2021
PubMed

Insights

Metastatic urothelial carcinoma (UC) has a poor prognosis. Antibody-drug conjugates (ADCs) offer a promising new treatment approach, delivering targeted therapies to improve survival for UC patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic urothelial carcinoma (UC) has a poor prognosis with less than 5% 5-year overall survival.
  • Standard treatments like chemotherapy and immune checkpoint inhibitors are insufficient for many patients.
  • Novel therapeutic strategies are urgently needed to improve outcomes in metastatic UC.

Purpose of the Study:

  • To review the potential of antibody-drug conjugates (ADCs) as a novel treatment for metastatic urothelial carcinoma.
  • To highlight the mechanism of action and emerging role of ADCs in UC therapy.

Main Methods:

  • Literature review of current research on antibody-drug conjugates (ADCs) for urothelial carcinoma.
  • Analysis of clinical trial data and FDA approvals related to ADCs in metastatic UC.

Main Results:

  • Antibody-drug conjugates (ADCs) utilize targeted antibody delivery of cytotoxic agents directly to tumor cells.
  • Enfortumab vedotin, an ADC, is approved for metastatic UC progressing after chemotherapy/immune checkpoint inhibitors.
  • Multiple ADCs are under investigation, showing promise in clinical trials for UC.

Conclusions:

  • Antibody-drug conjugates (ADCs) represent a significant advancement in the treatment of metastatic urothelial carcinoma.
  • ADCs offer a promising therapeutic option with a potentially improved survival benefit and acceptable toxicity profile for UC patients.
  • The development and investigation of ADCs are crucial for addressing the unmet medical needs in metastatic UC.
Keywords:
Bladder cancerUrothelial cancer

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.0K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
861
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K